09:15

Registration

09:30

WELCOME

Dieter Willbold

Heinrich Heine University Düsseldorf, Institut für Physikalische Biologie and

Forschungszentrum Jülich GmbH, IBI-7: Structural Biochemistry, Jülich, Germany

09:35

Welcome addresses

Prof. em. Dr. Dr. h.c. Detlev Riesner, Institut für Physikalische Biologie, Heinrich Heine University Düsseldorf, Germany

Michael Lorrain, Chairman Alzheimer Forschung Initiative e.V., Düsseldorf, Germany

SESSION I: Anti-amyloid antibody trials, outcome, meaningfulness and treatment costs

Chair: Janine Kutzsche, Forschungszentrum Jülich GmbH

09:45

Neurobiology of Alzheimer disease in people with Down syndrome

Elizabeth Head

Department of Pathology and Laboratory Medicine, University of California, Irvine,
CA, USA

10:35

Coffee break

11:00

Towards a future where Alzheimer’s disease is stopped before onset of dementia

Wiesje van der Flier

Alzheimer Centre, Department of Neurology, Amsterdam Neuroscience,
Vrije Universiteit Amsterdam, Netherlands

11:50

Clinical meaningfulness in the context of disease-modifying therapies: a complex concept

Lutz Frölich

Department of Geriatric Psychiatry, Zentralinstitut für Seelische Gesundheit
Mannheim, University of Heidelberg, Mannheim, Germany.

12:40

Study on the interaction of Abeta oligomers and Tau

Tina Jacob

Institut für Physikalische Biologie, Heinrich Heine University Düsseldorf, Germany

Talk by early career scientist

13:00

Lunch break

13:50

Key findings from two Phase III studies evaluating the efficacy and safety of subcutaneous gantenerumab in early Alzheimer’s disease (AD)

Frank Boess

F. Hoffmann-La Roche Ltd., Product Development Neuroscience, Basel, Switzerland

SESSION II: New concepts in therapy

Chair: Wolfgang Hoyer, Heinrich Heine University Düsseldorf

14:40

Vaccination with modified fungal proteins mimicking conformational epitopes on alpha-synuclein fibrils prolongs survival in mouse models of Parkinson's disease

Erdem Tamgüney^a and Holger Wille^b

^aInstitut für Physikalische Biologie, Heinrich Heine University Düsseldorf and Forschungszentrum Jülich GmbH, IBI-7: Structural Biochemistry, Jülich, Germany

^bCentre for Prions and Protein Folding Diseases & Department of Biochemistry,
University of Alberta, Edmonton, Canada

15:30

Coffee break

15:50

Detailed analysis of the structural changes in the α-synuclein amyloid aggregation pathways

José D. Camino

IBI-7, Forschungszentrum Jülich GmbH and Institute for Biocomputation and Physics of Complex Systems (BIFI), University of Zaragoza, Zaragoza, Spain

Talk by early career scientist

16:10

Anti-prionic therapy: disassembly of toxic prion-like aggregates for the treatment of neurodegenerative diseases

Antje Willuweit

Priavoid GmbH, Düsseldorf, Germany and Institute of Neuroscience and Medicine
(INM-4), Forschungszentrum Jülich GmbH, Jülich, Germany

17:00

Phosphorylation-state specific interaction of Aβ variants with RAGE

Lin Peng

Department of Neurology, Molecular Cell Biology, University Clinic Bonn, Germany

Talk by early career scientist

17:20

Break

PUBLIC SCIENCE LECTURE
jointly organized with Alzheimer Forschung Initiative e.V. (AFI)

18:15

Gemeinsam gegen das Vergessen: Informationsabend zu neuen Alzheimer-Therapien

Frank Jessen

Department of Psychiatry, Medical Faculty University of Cologne and German Center
for Neurodegenerative Diseases (DZNE), Bonn, Germany

SESSION III: Biomarkers and amyloid clearance

Chair: Erdem Tamgüney, Heinrich Heine University Düsseldorf

09:30

How fluid biomarkers revolutionize the diagnosis of Alzheimer´s disease

Oliver Peters

Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin and German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany

10:20

Rethinking Alzheimer's PET biomarkers using the spatial extent of pathology and neurodegeneration

Elena Doering

University of Cologne, Faculty of Medicine and University Hospital, Department of Nuclear Medicine, Cologne, Germany and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany

Talk by early career scientist

10:40

Coffee break

11:00

Stage 2 of AD as a target for DMT treatment

Frank Jessen

Department of Psychiatry, Medical Faculty University of Cologne and German Center
for Neurodegenerative Diseases (DZNE), Bonn, Germany

11:50

Oligomers count

Oliver Bannach

attyloid GmbH, Düsseldorf, Germany and Forschungszentrum Jülich GmbH, IBI-7: Structural Biochemistry, Jülich, Germany

12:40

Exploiting cross-amyloid interactions to design inhibitors of amyloid self-assembly

Aphrodite Kapurniotu

Division of Peptide Biochemistry, TUM School of Life Sciences, Technical University of Munich (TUM), Freising, Germany.

13:30

Lunch break

SESSION IV: Basic science: amyloid structures and early aggregation steps incl. LLPS

Chair: Gunnar Schröder, Forschungszentrum Jülich GmbH

14:20

Flash Talks Part 1

9 poster presenters, one single slide, 90 sec time per talk

14:40

Phase transitions of Tau: how liquid condensates catalyze pathological aggregation

Susanne Wegmann

German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany

15:30

Flash Talks Part 2,

10 poster presenters, one single slide, 90 sec time per talk

15:50

Funding Opportunities: Alzheimer Forschung Initiative e.V. (AFI)

Jochen Walter

Klinik für Neurologie, Universitätsklinikum Bonn, Germany

POSTER SESSION

16:00

Start poster session

17:30

Parallel to the poster session: finger food

17:30 and 18:00

Parallel to the poster session: Workshop of SuFIDA Helmholtz Innovation Lab

SESSION IV: Basic science: amyloid structures and early aggregation steps incl. LLPS

Chair: Birgit Strodel, Forschungszentrum Jülich GmbH

09:30

Structure dynamics of human PLCγ2 in auto-inhibition

Julie Chen and John Wang

Eisai, Center for Genetics Guided Dementia Discovery, Cambridge, Massacusetts, USA

10:20

Cryo-EM structures of amyloid-β fibrils from Alzheimer's disease Mouse Models

Fernanda S. Peralta Reyes

Institut für Physikalische Biologie, Heinrich Heine University Düsseldorf, Germany

Talk by early career scientist

CV – BEHIND THE SCENES

Chair: Birgit Strodel, Forschungszentrum Jülich GmbH

10:40

CV – behind the scenes

Frank Boess, Elizabeth Head, Aphrodite Kapurniotu and Holger Wille

The speakers report on their personal journey in academic and/or industrial research

11:40

Lunch break

SESSION IV: Basic science: amyloid structures and early aggregation steps incl. LLPS

Chair: Henrike Heise, Heinrich Heine University Düsseldorf

12:10

Cryo-EM structures of amyloid filaments from human brain

Sjors Scheres

MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge, UK

13:00

Structures and mechanisms of formation of amyloid-beta assemblies

Robert Tycko

Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and
Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA

13:50

Sequence and structural features that control aggregation into amyloid

Sheena Radford

Astbury Centre for Structural Molecular Biology, University of Leeds, United Kingdom

POSTER PRIZE AWARD

14:40

Poster prizes

sponsored by Alzheimer Forschung Initiative e.V.

Inga Kadish^a and Linda Thienpont^b

^aHeersink School of Medicine, Dept. Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, USA
^bAlzheimer Forschung Initiative e.V., Düsseldorf

14:50

Closing remarks

Inga Kadish^a, Thomas van Groen^b and Dieter Willbold^c (organizing committee)

^aHeersink School of Medicine, Dept. Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, USA
^bDept. Pediatrics-Neonatology, University of Alabama at Birmingham, USA
^cHeinrich Heine University Düsseldorf, Institut für Physikalische Biologie and Forschungszentrum Jülich, IBI-7: Structural Biochemistry, Jülich, Germany